Every material Form 8-K iBio, Inc. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its October 14, 2026 annual meeting, iBio stockholders approved raising authorized common stock from 275 million to 500 million shares, effective October 16, 2026 upon filing with Delaware. They also approved an amendment to the 2023 Omnibus Incentive Plan that adds shares to the plan each year, and re-elected two Class III directors. A larger pool of authorized shares gives the company room to issue more stock, which could dilute existing holders.
Authorized common stock rose from 275,000,000 to 500,000,000 shares; Certificate of Amendment filed October 16, 2026.
Authorized share increase approved with 45,730,093 votes for and 2,052,563 against.
Plan amendment approved with 27,693,575 votes for and 8,263,100 against; plan share reserve rises each January 1 from 2027 through 2033.
Two Class III directors, William Clark and Gary Sender, were elected to terms expiring at the 2029 annual meeting.
iBio presented preclinical data from an eight-week obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody, at the EASD Annual Meeting on October 1, 2026. The company reported that fat made up 93% of weight lost with IBIO-610 plus semaglutide, versus 77% with semaglutide alone, and it plans to begin first-in-human studies in the first half of 2027. The data are early animal results, and the filing notes they may not be replicated in humans.
Lean mass was 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone (eight-week study, n=6 per group)
At week 8, fat accounted for 93% of weight lost with IBIO-610 plus semaglutide, versus 77% with semaglutide alone
IBIO-610 reduced serum levels of active Activin E by 97% at week 8 after a single intravenous dose, and had a 33.2-day half-life in NHPs
First-in-human studies are planned to begin in the first half of 2027
iBio, Inc. filed an updated corporate presentation dated September 2026 as Exhibit 99.1 to a Form 8-K, for use in meetings with investors and analysts. The filing contains no new financial results, and the presentation reiterates pipeline timelines and a financial snapshot.
Presentation dated September 2026 furnished as Exhibit 99.1 under Items 7.01 and 8.01
Pipeline timelines include IBIO-610 IND-equivalent filing expected in 2H 2026 and IBIO-600 interim Phase 1 data anticipated in 1Q 2027
Financial snapshot shows $88.0 million in cash, cash equivalents and debt securities as of June 30, 2026, with runway extending into Q4 FY 2028
About 64.3 million shares outstanding as of August 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every iBio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →